Microbiome Face Cream for Eczema: Why More Bacterial Species Is Not a Clinical Result
AI-created illustration of a fictional adult with dermatitis-like cheek scaling. It is not a study participant, a microbiome test or a result from Dr. Arsy #003.
A face cream can change a laboratory measurement without demonstrating that it clears eczema. That distinction is especially useful when a product is described as “microbiome friendly” or “prebiotic.” Two recent studies help separate bacterial diversity measurements from outcomes that matter to someone managing a facial rash.
What the cheek study actually did
A 2025 single-site, open-label study included 12 adults aged 18–60 with eczema-prone and sensitive skin. They used one formulation twice daily for 21 days. It contained 2% colloidal oatmeal, Ophiopogon japonicus extract and proprietary filaggrin-related technology. Researchers collected cheek swabs before and after use.
The full primary report, pages 275–280 of the March issue, describes increased bacterial richness in ten of 12 participants, but no significant change in the Shannon index, overall composition by visit, individual taxa or the measured staphylococcal species. S. aureus was uncommon at baseline. Eczema severity and activity were not clinically scored. The study had no untreated or vehicle group. Two authors were Galderma employees; other relevant grants and advisory relationships were disclosed. The tested proprietary formulation was not #003.
What the different measurements mean for a reader
| Measurement | Question it addresses | Separate clinical question |
|---|---|---|
| Richness | How many different bacterial types were detected? | Did the facial rash improve? |
| Shannon diversity | How does diversity reflect both types and their relative distribution? | Did sleep, discomfort or daily function improve? |
| Overall composition | How similar are the sampled communities? | Did fewer clinically confirmed flares occur? |
| Individual bacterial abundance | Did a measured organism become more or less common? | Was an infection prevented or treated? |
These are related research interests, not interchangeable success measures. A before-and-after swab comparison is particularly limited when it lacks a concurrent control and does not record the disease outcome being advertised. It cannot tell a shopper that a different cream containing one shared ingredient produces the same effect.
A controlled short-term study found a different pattern
A separate randomized, operator-blinded study published online in 2025 included 15 people with atopic dermatitis and 15 healthy controls. Defined skin areas received moisturizer, farnesol, their combination or no treatment for seven days. Researchers used shotgun metagenomics. Neither treatment significantly changed richness, overall composition or core taxa in the AD group. Moisturizer modestly increased Shannon diversity in healthy skin.
That study used a different formulation, design, sampling context and duration; it was not a direct head-to-head facial cream comparison. A null finding in that experiment does not disprove the cheek study. Together, the reports show why a marketing claim needs the actual product, population, site, time and endpoint attached to it. The second study does not support adding a fragrance ingredient to an eczema routine at home.
A short checklist for a “microbiome” claim
Ask whether the evidence concerns your product or only an ingredient. Check whether participants had diagnosed active facial atopic dermatitis, self-described sensitive skin or healthy skin. Look for a comparison group and a clinical endpoint as well as a swab result. Finally, ask whether a reported change was statistically significant and clinically meaningful, rather than assuming that any movement in a laboratory number is beneficial.
Our facial formulation trial review discusses actual skin scores and its own reporting limitations. The healthy-volunteer sensitive-area study illustrates why the population matters. A selected head-and-neck dermatitis trial addresses another microbial hypothesis with different outcomes. For cleanser-related reactions, the CAPB testing report covers contact allergy rather than microbiome diversity.
What this means for #003
Dr. Arsy Moisturizer #003, 4 oz is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort where suitable. These studies did not test #003. They do not establish that it modifies the facial microbiome, prevents infection or treats eczema. Choose facial care within the diagnosis and treatment plan appropriate for your skin.